Leukemia News

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

As important as the care of Ukrainian citizens with cancer is to clinicians in that country, this priority has been overshadowed by more immediate concerns.

The FDA granted orphan drug designation to TCB-002 for treatment of adults with relapsed or refractory acute myeloid leukemia.

Among survivors of nine common cancers, risk for CV death overtook cancer mortality for most cancer subtypes among patients aged at least 80 years, researchers reported.

Just as physicians became accustomed to wearing pagers 40 years ago or being tied to smartphones 2 decades ago, many have become active on social media as it entered their practices.

An important component of cancer care is communication with patients and caregivers about their disease.

New cancer diagnosis appeared associated with increased risk for cardiovascular death, as well as incident heart failure, stroke or pulmonary embolism, according to a retrospective cohort study published in JACC: CardioOncology.

Most cancer drug approvals between 2016 and 2021 applied to second-, third- or later-line treatment settings and did not displace current standard-of-care therapies, according to a study published in JAMA Network Open.

The FDA granted orphan drug designation to NTLA-5001 for treatment of adults with relapsed or refractory acute myeloid leukemia.